Gilead Sciences, Inc. (GILD) Now Covered by Analysts at Oppenheimer Holdings, Inc.
Oppenheimer Holdings, Inc. assumed coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report report published on Thursday morning. The brokerage issued a market perform rating on the biopharmaceutical company’s stock.
GILD has been the subject of a number of other research reports. William Blair reiterated an outperform rating on shares of Gilead Sciences in a report on Friday, June 16th. Morgan Stanley reiterated an equal weight rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Royal Bank Of Canada started coverage on Gilead Sciences in a report on Thursday, September 14th. They issued an outperform rating and a $94.00 price target for the company. Robert W. Baird reiterated an outperform rating and issued a $87.00 price target on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Berenberg Bank set a $86.00 price target on Gilead Sciences and gave the company a buy rating in a report on Tuesday, August 29th. Twelve investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $85.66.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.64% on Thursday, hitting $82.14. The stock had a trading volume of 5,797,031 shares. The company has a market cap of $107.27 billion, a P/E ratio of 8.92 and a beta of 1.14. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a 50-day moving average of $80.69 and a 200-day moving average of $71.56.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.08 earnings per share. On average, equities analysts anticipate that Gilead Sciences will post $8.75 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/06/gilead-sciences-inc-gild-now-covered-by-analysts-at-oppenheimer-holdings-inc.html.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.
In other news, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Over the last three months, insiders have sold 486,819 shares of company stock worth $39,298,919. Corporate insiders own 1.30% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Waldron LP raised its holdings in Gilead Sciences by 20.4% in the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock valued at $711,000 after acquiring an additional 1,752 shares during the last quarter. Mycio Wealth Partners LLC increased its holdings in shares of Gilead Sciences by 13.0% during the 1st quarter. Mycio Wealth Partners LLC now owns 10,146 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 1,165 shares during the last quarter. Cubic Asset Management LLC increased its holdings in shares of Gilead Sciences by 1.9% during the 1st quarter. Cubic Asset Management LLC now owns 29,701 shares of the biopharmaceutical company’s stock worth $2,017,000 after buying an additional 560 shares during the last quarter. Dubuque Bank & Trust Co. increased its holdings in shares of Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the last quarter. Finally, Adviser Investments LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $4,218,000. 73.99% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.